NEW YORK – Accelerate Diagnostics and BioCheck announced on Tuesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a COVID-19 serology assay and test system.
The BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument will be marketed and commercialized by Accelerate Diagnostics following a commercial supply and collaboration agreement the firms forged in April.